or Try an Advanced Search...

    Technical Analysis for ELVN - Enliven Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 23.37 -0.34% -0.08
    ELVN closed down 0.34 percent on Friday, June 28, 2024, on 7.02 times normal volume.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ELVN trend table...
    Date Alert Name Type % Chg
    Volume Surge Other 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Crossed Above 20 DMA Bullish -0.34%
    Crossed Above 50 DMA Bullish -0.34%
    MACD Bullish Centerline Cross Bullish -0.34%
    MACD Bullish Signal Line Cross Bullish -0.34%
    Expansion Pivot Buy Setup Bullish Swing Setup -0.34%
    Bollinger Band Squeeze Range Contraction -0.34%
    Older End-of-Day Signals for ELVN ...

       Recent Intraday Alerts

    Alert Time
    Up 3% 2 days ago
    Up 2% 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    Up 1% 2 days ago
    Down 1% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ELVN Chart by TradingView
    Basic chart:

    Profile

    Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia

    Is ELVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 29 Enliven Therapeutics to Present at Two Upcoming Investor Conferences
    May 15 Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02
    May 14 Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
    Apr 19 MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
    Apr 18 Enliven Therapeutics files to sell 6.43M shares for holders
    Apr 11 Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
    Apr 11 Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
    Apr 9 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
    Apr 9 Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),
    Mar 28 Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
    See more ELVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.0
    52 Week Low 9.84
    Average Volume 362,387
    200-Day Moving Average 16.10
    50-Day Moving Average 21.48
    20-Day Moving Average 21.65
    10-Day Moving Average 21.75
    Average True Range 1.51
    RSI (14) 58.51
    ADX 14.61
    +DI 27.48
    -DI 17.44
    Chandelier Exit (Long, 3 ATRs) 19.70
    Chandelier Exit (Short, 3 ATRs) 24.06
    Upper Bollinger Bands 23.46
    Lower Bollinger Band 19.84
    Percent B (%b) 0.97
    BandWidth 16.74
    MACD Line 0.18
    MACD Signal Line 0.04
    MACD Histogram 0.1478
    Fundamentals Value
    Market Cap 963.12 Million
    Num Shares 41.2 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -25.40
    Price-to-Sales 0.00
    Price-to-Book 2.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 25.25
    Resistance 3 (R3) 25.33 24.78 24.93
    Resistance 2 (R2) 24.78 24.31 24.74 24.83
    Resistance 1 (R1) 24.08 24.01 23.81 24.00 24.73
    Pivot Point 23.53 23.53 23.40 23.49 23.53
    Support 1 (S1) 22.83 23.05 22.55 22.74 22.01
    Support 2 (S2) 22.28 22.76 22.24 21.91
    Support 3 (S3) 21.57 22.28 21.81
    Support 4 (S4) 21.49